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TGF-b1 is a known inhibitor of branching morphogenesis when added exogenously to mouse embryonic lungs in culture.
However, the issue of whether endogenous TGF-b signaling has a function in the process of lung organogenesis is not
completely resolved. We utilized immunoperturbation and antisense oligodeoxynucleotide inhibitory strategies to abrogate
TGF-b type II receptor function in embryonic mouse lungs undergoing branching morphogenesis in serumless explant
culture. Antisera directed against a TGF-b type II receptor N-terminal peptide that perturbs TGF-b ligand±receptor binding
increased branching by 70%. Similarly, antisense TGF-b type II receptor oligodeoxynucleotides (40 mM) resulted in a 58%
increase in branching, compared to scrambled and mismatched sequence controls, while TGF-b type II receptor mRNA
and its protein expression levels were suppressed by 95 and 84%, respectively. Addition of exogenous TGF-b1 did not
overcome the stimulatory effects either of TGF-b type II receptor immunoperturbation or of antisense oligodeoxynucleotide
treatment on lung branching morphogenesis. Using in situ hybridization and immunohistochemistry, both TGF-b type II
receptor mRNA and protein were localized to the epithelium lining the developing airways, and to the surrounding
mesenchyme, indicating that TGF-b type II receptor is an important regulator of epithelial±mesenchymal interaction.
Exogenous TGF-b1 decreased cyclin A mRNA levels in control embryonic lung explants, while TGF-b type II receptor
antisense oligodeoxynucleotides prevented the downregulation of cyclin A mRNA expression by exogenous TGF-b1. In
addition, PCNA immunostaining of the primitive bronchial epithelium was increased in the presence of TGF-b type II
receptor antisense oligodeoxynucleotides either alone or together with exogenous TGF-b1, whereas TGF-b1 alone decreased
PCNA staining. Thus, abrogation of TGF-b type II receptor expression prevented TGF-b1-induced epithelial cell G1 arrest.
These results demonstrate, for the ®rst time, that abrogation of the TGF-b type II receptor stimulates embryonic lung
organogenesis in culture and reverses the negative in¯uence of endogenous TGF-b signaling upon epithelial cell cycle
progression. q 1996 Academic Press, Inc.
INTRODUCTION malian organs including the lung, kidney, breast, pancreas,
prostate, salivary glands, sweat glands, and gastrointestinal
Epithelial±mesenchymal inductive interactions are a crypts. Autocrine or paracrine stimulation by peptide
common paradigm in the morphogenesis of branched mam- growth factors of cognate membrane bound receptors as
well as cell±matrix interactions have been implicated as
mediating or modulating these inductive processes, yet the1 The ®rst two authors contributed equally to this work.
organ-speci®c function of signaling by speci®c classes of2 Present address: Of®ce of the Director, NIDR, National Insti-
cognate receptors remains largely obscure.tutes of Health, Bethesda, Maryland.
The lung forms as paired ventral outgrowths from the3 To whom correspondence should be addressed at USC Center
primitive foregut endoderm that progressively invade thefor Craniofacial Molecular Biology, 2250 Alcazar Street, CSA 103,
surrounding mesenchyme in a genetically predeterminedLos Angeles, CA 90033. Fax: (213)342-2981. E-mail: dwarburton
%smtpgate@chlais.usc.edu. pattern of branching morphogenesis and organ-speci®c cell
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burton et al., 1992; Seth et al., 1993; Minoo et al., 1995). E11 lungdifferentiation (reviewed in Minoo and King, 1994). Mesen-
explants were placed on 0.80-mm MF-Millipore ®lters (Millipore,chyme recombination studies have clearly demonstrated
Bedford, MA) supported by stainless-steel grids in Grobstein culturethat peripheral embryonic lung mesenchyme can induce
dishes (Falcon, Lincoln Park, NJ) and cultured in BGJb mediumectopic branching as well as expression of peripheral lung-
(Gibco, Grand Island, NY) supplemented with 0.1 mg/ml ascorbicspeci®c genes when transplanted adjacent to proximal lung
acid and 50 units/ml penicillin/streptomycin. About 1 ml medium
epithelium in embryonic lung in culture, and that this effect was added to each dish (10 explants per dish) to establish an air±
is mediated by soluble factors (Alescio and Cassini, 1962; ¯uid interface at the level of the explants. The cultures were main-
Shannon, 1994). tained in 100% humidity with an atmosphere of 95% air and 5%
Candidate inductive peptide growth factors for pulmo- CO2 for 4 days. The medium was changed every 2 days.
nary morphogenesis include EGF, bFGF, PDGF, and TGF-
b3, all of which exert inductive or permissive in¯uences on
Exposure to Exogenous TGF-b1 and TGF-b2lung development as demonstrated by gain and/or loss of
function experiments either in early embryonic mouse lung
E11 embryonic mouse lungs were cultured for 4 days in the pres-
organ culture, in transgenic mice, or in null mutant mice ence of known concentrations of TGF-b1 (0.2, 5, 10, or 20 ng/ml)
(Raaberg et al., 1991, 1995; Warburton et al., 1991, 1992; or TGF-b2 (0.05, 0.1, or 0.5 ng/ml) added to the culture medium
Peters et al., 1994; Kaartinen et al., 1995; Miettinen et al., from aqueous stock solutions. Activated TGF-b1 and TGF-b2 were
1995; Souza et al., 1995; BostroÈ m et al., 1996). On the other graciously provided by Dr. James Dasch of Celtrix Pharmaceuticals
hand, both addition of exogenous TGF-b1 to embryonic (South San Francisco, CA).
mouse lungs in culture and organ-speci®c overexpression
of TGF-b1 in transgenic mice bearing a chimeric SP-C pro-
TGF-b Type II Receptor Immunoperturbationmoter-directed TGF-b1 expression construct result in hypo-
plastic phenotypes (Serra et al., 1994; Serra and Moses, 1995;
We used an antiserum raised in rabbit using a 28-residue syn-
Zhou et al., 1996), indicating that exogenous TGF-b1 exerts thetic peptide corresponding to amino acids 24±51 of the human
a negative regulatory in¯uence on lung morphogenesis. TGF-b type II receptor cDNA sequence as the immunogen (Lin et
TGF-b ligand binds to the TGF-b type II receptor and al., 1992; Hall et al., 1996). This epitope is located in the extracellu-
triggers heterodimerization with TGF-b type I receptor lar N-terminal domain. This peptide sequence subsequently proved
(MassagueÂ et al., 1990; Roberts et al., 1990; Chai et al., to be 75% identical to the murine sequence in this region and has
been characterized as speci®cally identifying the type II receptor1994). Following heterodimerization, the TGF-b type II re-
of mouse, rat, mink, and human on Western analysis. TGF-b typeceptor serine/threonine kinase transphosphorylates the
II receptor antiserum was used to abrogate TGF-b signaling duringtype I receptor, resulting in the propagation of a phosphory-
early mouse embryonic lung branching morphogenesis in vitro.lation signal to downstream substrates (Wrana et al., 1994).
This antibody, binding to the extracellular domain of the TGF-bThus, it appears that expression and signaling by the TGF-
type II receptor, interferes with ligand binding by type I and type
b type II receptor is crucial to the integrity of the TGF-b II receptors, thereby perturbing TGF-b signaling (Hall et al., 1996).
signal transduction pathway. The rabbit antiserum was added to the cultures in a ®nal concentra-
Herein, we have tested the hypothesis that the TGF-b tion of 1%. Explants were also cultured in the presence of 1% fetal
type II receptor functions as an endogenous regulator of bovine serum to control for the nonspeci®c effects of 1% serum.
branching morphogenesis in the early embryonic mouse Additional explants were maintained in the presence of both 1%
TGF-b type II receptor antisera and an effective inhibitory concen-lung. We devised two strategies to effectively inhibit TGF-
tration of TGF-b1 (10 ng/ml) to con®rm perturbation of TGF-bb type II receptor function using immunoperturbation and
receptor signaling by the antiserum.antisense oligodeoxynucleotides (ODN). We found that ab-
rogation of TGF-b type II receptor function stimulates lung
morphogenesis, partly through the release of endogenous
TGF-b Type II Receptor Antisensenegative modulation of the epithelial cell cycle, indicating
Oligodeoxynucleotide Inhibitionthat endogenous TGF-b type II receptor signaling functions
as a negative modulator of lung morphogenesis. TGF-b type II receptor antisense oligodeoxynucleotide (ODN) 5*-
CATGGCAGCCCCCGTC-3* (16-mer) was synthesized based on
nucleotide sequence of the murine TGF-b type II receptor cDNA
sequence (Lawler et al., 1994). The antisense ODN was designedMATERIALS AND METHODS
to surround the type II receptor translation initiation site. Two
same-length control ODNs were also synthesized: (1) 5*-TCCGCA-Organ Culture
GCGTCCACCG-3* (same nucleotide composition but scrambled
sequence); (2) 5*-CATGGCTGCCCCCGAC-3* (same nucleotideTimed-pregnant Swiss±Webster mice were sacri®ced on Postcoi-
tum Day 11 (E11) and the embryos were removed. Lung primordia sequence except the underlined A and T were mismatched by
switching the position). The ®rst three and the last three baseswere isolated from embryos (E11) by microdissection. Dissection
was carried out under sterile conditions using microophthalmic in each ODN sequence were modi®ed by phosphorothioation to
improve stability against nuclease degradation in culture. Thesurgical instruments and a dissecting microscope. Early mouse em-
bryonic lungs (E11) were cultured under serum-free, chemically ODNs were subsequently puri®ed by HPLC (USC Comprehensive
Cancer Center, Los Angeles, CA). Antisense, scrambled, or mis-de®ned conditions as reported previously (Jaskoll et al., 1988; War-
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matched ODNs were added to early mouse embryonic lung cultures et al., 1990). TGF-b type II receptor competitor PCR products using
primers I and II were 600 bp in length. The identity of the TGF-bin aqueous solution to achieve ®nal concentrations of 20 or 40 mM.
Several technical caveats are inherent to this experimental ap- type II receptor and its competitor were both con®rmed by DNA
sequencing (Sanger et al., 1977).proach (Neckers and Whitesell, 1993). At least two possible mecha-
nisms might contribute to downregulate target gene expression A similar method was utilized for primer design and competitor
template construction for both cyclin A and cyclin D1 as for TGF-(Wagner, 1994): ®rst, antisense ODN binds to its target transcript
and blocks accumulation of translational initiation complexes, b type II receptor. Cyclin A cDNA is 328 bp and its competitor is
430 bp in length (Ravnik and Wolgemuth, 1996). Both cyclin Athus terminating speci®c protein synthesis; second, antisense
ODN±mRNA hybrids are a better target for nuclease and are there- cDNA and its competitor used the same set of speci®c primer in
cyclin A competitive PCR. Cyclin D1 cDNA is 362 bp and itsfore more susceptible to message degradation. The range of ODN
concentrations used in the current experiments is known to be competitor is 480 bp in length (Smith et al., 1995). Both cyclin D1
cDNA and its competitor also used the same set of primer speci®ceffective in our serumless embryonic lung explants and confers
suf®cient speci®city of hybridization to target mRNA (Seth et al., to cyclin D1 competitive PCR. Identity of both cyclin A and cyclin
D1 competitive PCR products were con®rmed by DNA sequencing.1993). However, unmodi®ed ODN could be rapidly turned over in
culture media and therefore fail to hybridize to the target gene
(Neckers and Whitesell, 1993; Wagner, 1994). Therefore, the ODNs
Competitive PCRin our study were modi®ed with phosphorothioates at nucleotides
lying at the end of the sequences to provide relatively greater stabil-
PCR ampli®cation was carried out in a DNA Thermal Cyclerity in culture media. It seems that serum-free culture conditions
(Perkin Elmer Cetus, Foster City, CA) using a modi®cation of acan also enhance the stability of ODN (Neckers and Whitesell,
previously described assay for matrix Gla protein (Zhao et al., 1995;1993; Minoo et al., 1995). We designed the TGF-b type II receptor
Zhao and Nishimoto, 1995, 1996). Thirty-®ve cycles of denatur-antisense ODN to include the sequence ¯anking the translation
ation at 937C for 2 min, annealing at 627C for 2 min, and extensioninitiation codon, the area known empirically to be most effective
at 727C for 2 min were routinely performed after an initial 3-minin inhibiting translation of target mRNA (Marcus-Sekura, 1988).
denaturation at 947C. The ®nal cycle included a 5-min extensionWe used scrambled control ODN sequences selected to contain the
step. The reaction mixture contained 10 mM Tris (pH 9.4), 50 mMsame base composition as the antisense sequence since a scrambled
KCl, 2 mM MgCl2 (optimized), 0.01% gelatin, 0.1% Triton X-100,sequence may provide a better control for nonspeci®c nucleotide
20 pmol primer sets, 100 mM dNTP, and 0.5 unit Taq thermostablebreakdown toxicities than the more conventional sense ODN con-
DNA polymerase (Promega, Madison, WI). Reaction mixture con-trol (Neckers and Whitesell, 1993; Wagner, 1994; Minoo et al.,
taining a known amount of TGF-b type II receptor competitor was1995).
added to reverse-transcribed samples derived from 50 ng total RNA
or to dilutions of standard TGF-b type II receptor cDNA templates
in a total volume of 50 ml. Concentration of cDNA standard solu-Quantitation of Branching Morphogenesis
tions were determined spectrophotometrically upon absorbance at
260 nm using 1 A260  50 mg/ml. Primers and templates construc-Branching morphogenesis was expressed as the number of epithe-
tion for b-actin competitive PCR was described previously (Zhaolial sacs visible around the periphery of the lung explants. The
et al., 1995). Methodology of cyclin A or cyclin D1 competitiveanalyses were performed (a) on whole mounts of lung explants,
PCR was similar to that of TGF-b type II receptor. Only 20 ngusing transillumination to visualize structures, and photomicro-
reverse-transcribed total RNA was used in both cyclin A and cyclingraphy to record permanent images and (b) on paraf®n histological
D1 competitive PCR. The procedure for b-actin competitive PCRsections of ®xed material. In either case, both lungs were counted.
was similar to that of TGF-b type II receptor as documented else-
where (Zhao et al., 1995).
Primers and Templates for TGF-b Type II
Receptor, Cyclin A, and Cyclin D1 Competitive Electrophoresis and Densitometric AnalysisRT±PCR
Electrophoresis was performed on 3% agarose gels (3:1 mixture
A set of primers was designed based on the murine TGF-b type of Nusieve and Seakem, FMC, Rockland, ME) in a Max Submarine
II receptor cDNA sequence: Primer 1 (upstream) was 5*-CAGGGA- Unit (Hoefer, San Francisco, CA), where target and competitor PCR
CCTCAAGAGCTCTAAC-3 * and primer II (downstream) was 5*- products were separated by size. Gels were stained with 5 mg/ml
GTCCATATGCTCCAGCTCACTG-3* (Lawler et al., 1994). TGF- ethidium bromide and photographed by Polaroid 667 ®lms. The
b type II receptor cDNA was thus obtained by PCR ampli®cation intensity was determined by densitometric analysis using Im-
using primers I and II in reverse-transcribed products from embry- ageQuan band-analyzing software (Molecular Dynamics, Sun-
onic murine lung and the PCR product length was 505 bp (Fig. 4A). nyvale, CA).
Subsequently, two composite primers were used for type II receptor
competitor construction (Fig. 4A): each composite primer had the
target type II receptor gene primer sequence (black box) attached RNA Extraction and Reverse Transcription
to a short stretch of sequence (hatched box) designed to hybridize
to opposite strands of a heterogeneous DNA fragment. The desired Total RNA from individual cultured lung explants was extracted
by guanidinium thiocyanate following homogenization utilizing aprimer sequences were thus incorporated into the heterogeneous
fragment during the PCR ampli®cation. This ensured that all TGF- total RNA isolation kit from 5 Prime r 3 Prime (West Chester,
PA). Extracted total RNA was reverse transcribed as described pre-b type II receptor competitor molecules had the same gene-speci®c
primer sequences as the TGF-b type II receptor cDNA. The hetero- viously (Araki et al., 1993). Samples were incubated at 377C for 1
hr in 20 ml of 10 mM Tris (pH 8.4), 50 mM KCl, 2 mM MgCl2, 1geneous DNA was derived from a piece of v-erbB DNA (Bruskin
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mM dithiothreitol, 5 units ribonuclease inhibitor, 0.5 mM dNTP, tions (6 mm thick) were air-dried on poly-L-lysine-coated slides and
deparaf®nized. TGF-b type II receptor immunostaining was pro-100 pmol oligo(dT)12±18, and 200 units of M-MLV reverse tran-
scriptase (USB, Cleveland, OH). The reaction was terminated by cessed using the same antibody (1:100 dilution) as described for
Western blot. PCNA immunohistochemistry was performed usingheating for 5 min at 957C. Reverse-transcribed products were then
used for competitive PCR assay. the mouse monoclonal IgG2a antibody PC10 (Santa Cruz Biotech.)
at a dilution of 1:200. Biotinylated secondary antibody and streptav-
idin-HRP conjugate was used to detect bound antibody. Subsequent
Western Analysis of TGF-b Type II Receptor addition of AEC (aminoethyl carbazole) chromogen generated a red-
Protein dish precipitate around the TGF-b type II receptor or PCNA antigen
(Zymed, South San Francisco, CA). As a negative control, mouseIndividual lung explants were harvested after culture and placed
IgG2a was substituted for the primary antibody.in a lysis buffer containing 1.0% Triton X-100, 0.5% NP-40 and
For PCNA, sections were counterstained with hematoxylin andprotease inhibitors. The total protein concentration in each lung
then visualized and photographed. Lung sections were examinedsample was determined using the micro-BCA protein assay reagent
by light microscopy at high magni®cation. Surface epithelial cellkit (Pierce, Rockland, IL). Five micrograms total protein from each
nuclei in the bronchial cross section were examined and classi®edsample was loaded in each well on a 7.5% Tris±glycine polyacryl-
as PCNA positive (red nuclei from AEC staining) or PCNA negativeamide gel. The electrophoresis was undertaken in a modular mini-
(blue nuclei from hematoxylin staining). At least 1000 cells aroundProtean II electrophoresis system (Bio-Rad, Hercules, CA). Protein
the entire circumference of each bronchial cross section wereon the gel was then transferred to a Millipore Immobilon-P mem-
counted. The PCNA index (percentage of PCNA-positive nuclei)brane by using a Bio-Rad mini-trans-blot electrophoretic transfer
was thus determined and its mean value represented an averagecell. Equal transfer ef®ciency for each sample was con®rmed by
from at least 10 individual lung sections under each condition.Coomassie blue stain of the membrane after Western blot. The
antibody (rabbit polyclonal IgG) against TGF-b type II membrane
receptor was purchased from Santa Cruz Biotech. (Santa Cruz, CA).
Statistical analysisThe immunizing epitope corresponds to amino acids 550±565 map-
ping within the carboxyterminal domain of human TGF-b type II
All explant experiments were repeated at least three to fourreceptor and the antibody is mouse reactive. The subsequent West-
times, with similar results obtained within repetitive experiments.ern blot was performed utilizing a chemiluminescence Western
Statistical signi®cance was tested by two-way analysis of variance
blotting kit (Boehringer Mannheim, Indianapolis, IN). A ®nal con-
with Neuman±Kuells correction applied for small samples. A P 
centration of 50 ng/ml antibody was incubated with membrane at
0.05 was accepted as statistically signi®cant.
47C overnight. Then, 500 mUnits/ml POD (horseradish peroxi-
dase)-labeled secondary antibody was added to incubate with mem-
brane for 30 min. The chemiluminescent light was captured by
Kodak X-Omat AR ®lm for a permanent record. The TGF-b type RESULTS
II receptor antibody binds to a 70-kDa band on the membrane.
This band was diminished and its intensity was greatly reduced by TGF-b1 and TGF-b2 Exert Differential Inhibitory
preabsorption of the antibody with an excess amount of control Effects on Lung Branching Morphogenesis in
antigen peptide (data not shown). Bovine serum albumin was also
Cultureused as a negative control and was not recognized by type II receptor
antibody (data not shown). Mouse lungs excised from E11 embryos, which consist of
the rudimentary trachea and the primary branched major
bronchi (Fig. 1A), undergo normal, although reduced (com-TGF-b Type II Receptor in Situ Hybridization
pared to in vivo) branching morphogenesis (Fig. 1B) in a
A partial TGF-b type II receptor cDNA (204 bp) was cloned into chemically de®ned serum-free medium without the admin-
pCR II vector (Invitrogen, San Diego, CA). Antisense and sense
istration of any exogenous factors. In this organ culturecRNA probes were made by using SP6 and T7 RNA polymerases
system, addition of TGF-b1 or of TGF-b2 both inhibitedwith digoxigenin-labeled UTP (Boehringer Mannheim, Indianapo-
lung explant branching by reducing the number of airwaylis, IN). In situ hybridization was performed as described previously
generations and appeared to prevent septation of the periph-(Zhao and Nishimoto, 1996), with modi®cations to embryonic lung
eral airways (Figs. 1C and 1D). However, a low concentra-tissues. Several negative controls were run in parallel with the
experimental reactions: (1) sections were processed without labeled tion (0.2 ng/ml) of exogenous TGF-b1 also stimulated
riboprobe; (2) sections were incubated in hybridization solution branching morphogenesis by 10% (P  0.05), while no such
containing the sense riboprobe; and (3) sections were treated with effect was observed for TGF-b2 (data not shown). At higher
RNase A prior to hybridization. To determine probe speci®city, two concentrations, both TGF-b1 and TGF-b2 reduced the num-
other partial TGF-b type II receptor cDNA clones bearing different ber of airway generations in a concentration-dependent
sequence domains were cloned. These riboprobes resulted in same
manner (Fig. 2). Addition of 20 ng/ml TGF-b1 reduced thehybridization patterns on tissue specimen as the TGF-b type II
number of terminal branches to 66% of the control (Fig.receptor probe described above.
2A), while only 0.5 ng/ml exogenous TGF-b2 was required
to decrease the number of terminal branches to 69% of
Immunohistochemistry and Morphometry control (Fig. 2B) (P  0.05). Thus, the inhibitory effects of
exogenous TGF-b2 (IC50  0.1 ng/ml, IC50 , concentrationCultured lung explants were ®xed immediately upon harvest and
embedded into paraf®n subsequently. Embryonic lung explant sec- at 50% of maximal inhibition) were 50 times more potent
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FIG. 2. Exogenous TGF-b1 and TGF-b2 isoforms differentially
attenuate branching morphogenesis in murine embryonic lung ex-
plant cultures. The number of terminal branches developed in both
lungs was measured after 4 days in serum-free de®ned medium.
Each bar represents mean from 10 lung explants and error bar indi-
cates standard deviation. Both isoforms decrease branching in a
concentration-dependent manner. However, TGF-b1 (A) is 50-fold
less potent than TGF-b2 based on IC50 (B).
than TGF-b1 (IC50  5 ng/ml) (P  0.001) (Fig. 2). The latter
®ndings are consistent with a signaling pathway exhibiting
differential sensitivity to exogenous TGF-b1 and TGF-b2.
Immunoperturbation with TGF-b Type II Receptor
Antibody Stimulates Lung Branching
Morphogenesis in Vitro
Stimulation of branching morphogenesis was observed in
the presence of anti-TGF-b type II receptor antibody (Fig.
1G). The antibody was designed to recognize an extracellu-
FIG. 1. Branching morphogenesis in murine lung explant cul-
tures. Embryonic lung obtained at 11 days gestation (A) and cul-
tured for 4 days in a de®ned serum-free medium developed a charac-
teristic branching pattern (B). Addition of 10 ng/ml TGF-b1 (C) or
0.1 ng/ml TGF-b2 (D) decreased in vitro branching. Antisense ODN
(40 mM) complementary to the TGF-b type II receptor mRNA (F)
increased branching relative to medium control (B) or 40 mM scram-
bled ODN treatment (E). Addition of exogenous TGF-b1 could not
overcome the stimulatory effect on branching by antisense ODN
(J), whereas TGF-b1 administration showed a similar inhibitory
effect on lung branching in the presence of scrambled ODN (I) as
in plain media (C). Interruption of TGF-b receptor signaling by
immunoperturbation using anti-TGF-b type II receptor antisera (G)
also increased branching relative to controls (B). Immunoperturba-
tion could not be reversed by addition of exogenous TGF-b1 (H).
Bar represents 150 mm in length.
Copyright q 1996 by Academic Press, Inc. All rights of reproduction in any form reserved.
AID DB 8378 / 6x14$$$383 11-06-96 19:09:15 dba AP: Dev Bio
247TGF-b-IIR Abrogation Stimulates Embryonic Lung Branching Morphogenesis
FIG. 3. Regulation of branching morphogenesis by TGF-b signaling pathway. The number of terminal branches developed in both lungs
of explants was measured after culture in medium in for 4 days. Each bar represents the mean from 10 lung explants and the error bar
indicates one standard deviation. TGF-b1 (10 ng/ml) treatment (b1) decreased branches over control (Ctrl Medium). Inhibition to TGF-b
type II receptor expression by 40 mM antisense ODN (AS-IIR) resulted in a signi®cant increase in lung branching comparing to media control
(Ctrl Medium), 40 mM scrambled ODN (SR-IIR), or 40 mM mismatched ODN controls (MM-IIR), while both scrambled or mismatched ODN
to TGF-b type II receptor mRNA had similar terminal branches to medium control (Ctrl Medium). Administration of 10 ng/ml TGF-b1
could not overcome the stimulatory effect of lung branching by antisense ODN (AS-IIR/b1 and AS-IIR), whereas cotreatment of 10 ng/
ml TGF-b1 and scrambled ODN (SR-IIR/b1) on lung explants in culture resulted in a similar inhibitory effect on branching in comparison
to TGF-b1 treatment to lung explants in plain media (b1). Similarly, abrogation of TGF-b signaling by anti-TGF-b type II receptor antisera
(IIR-Ab) increased the number of terminal branches developed relative to serum-free (Ctrl Medium) or fetal bovine serum controls (Ctrl
Serum), effects which could not be overridden by addition of 10 ng/ml exogenous TGF-b1 (IIR-Ab/b1). Abbreviations: Ctrl, Control; b1,
TGF-b1; IIR, TGF-b type II receptor; SR, scrambled; MM, mismatched; AS, antisense; Ab, antibody.
lar N-terminal peptide of the TGF-b type II receptor and has morphogenesis in early mouse embryonic development, an
been shown to result in perturbation of the TGF-b signaling antisense oligodeoxynucleotide strategy was developed. A
pathway (Hall et al., 1996). Signi®cant stimulation of 16-mer antisense ODN was chosen to surround the mouse
branching (70%, P  0.05) was observed in the presence of TGF-b type II receptor initiation site. Lung rudiments from
1% antibody against type II receptor (Fig. 3, IIR-Ab). No E11 embryos were explanted in culture in the presence of
nonspeci®c effect of serum at this concentration was noted two nontoxic doses (20 and 40 mM) of TGF-b type II receptor
in 1% fetal bovine serum controls (Fig. 3, Ctrl serum), which antisense ODN. Two control ODNs of the same length,
gave identical branching to the media control. In Figs. 1C scrambled ODN (same base composition with randomly
and 2A, 10 ng/ml TGF-b was observed to signi®cantly in- scrambled sequence) and mismatched ODN (with only two
hibit branching (P  0.05). However, addition of exogenous base mismatches), were used as alternatives to an antisense
TGF-b1 at this concentration (10 ng/ml) in the presence of ODN control. After 4 days in culture, lungs were harvested
1% type II receptor antiserum did not result in any signi®- and photographed (Figs. 1E and 1F). It was apparent that
cant reduction in the number of terminal branches in com- inhibiting TGF-b type II receptor with antisense ODN stim-
parison with 1% antiserum only (Fig. 3, IIR-Ab and IIR-Ab/ ulated lung branching morphogenesis in comparison with
b1). The ®nding that 10 ng/ml exogenous TGF-b1 could the controls (Figs. 1B, 1E, and 1F). The extent of branching
not overcome the stimulation of branching morphogenesis was quantitated by counting the number of terminal
in the presence of 1% anti-TGF-b type II receptor antiserum
branches. Branching was increased by 58% (Fig. 3, AS-IIR)
con®rmed the abrogation of the TGF-b signaling pathway
in the presence of 40 mM TGF-b type II receptor antisenseby the type II receptor antibody. These results support the
ODN treatment (P  0.05), while the same concentrationconclusion that abrogating TGF-b signaling by immunoper-
either of scrambled or of mismatched ODN had no effectturbation reversed negative regulation of branching mor-
on branching (Fig. 3, SR-IIR and MM-IIR) compared to thephogenesis by the endogenous TGF-b signaling pathway.
media control (Ctrl Medium). Furthermore, cotreatment of
Attenuation of Endogenous TGF-b Type II lung explant culture with both TGF-b1 and antisense ODN
Receptor Signaling with Antisense to its type II receptor resulted in a similar stimulatory effect
Oligodeoxynucleotides Stimulates Lung Branching on branching to antisense ODN alone (Fig. 3, AS-IIR/b1 and
Morphogenesis in Vitro AS-IIR), while TGF-b1 was able to inhibit branching in the
presence of either scrambled (SR-IIR/b1) or mismatchedTo further examine the possibility that inhibition of TGF-
b type II receptor gene expression modulates lung branching (not shown) ODN. This evidence indicates that TGF-b1
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loses its ability to inhibit branching morphogenesis while
its type II receptor is abrogated. These results further sup-
port the conclusion that abrogation of TGF-b type II recep-
tor expression releases negative regulation of branching
morphogenesis by the endogenous TGF-b signaling system.
Measurement of TGF-b Type II Receptor mRNA
Levels by Competitive RT±PCR
A highly sensitive and quantitative competitive RT±PCR
method was utilized to measure the endogenous type II
receptor mRNA amounts in lung explant cultures. We have
previously shown that competitive RT±PCR is ideal for
low abundance mRNA determination in small samples, and
enabled both accurate and quantitative TGF-b type II recep-
tor-speci®c mRNA levels to be determined in single lung
explants.
Sequential 1:2 dilutions of mouse TGF-b type II receptor
cDNA template were prepared. A constant amount (1.25 fg)
of type II receptor cDNA template was also added to each
tube. After PCR coampli®cation of both mouse type II re-
ceptor cDNA serial dilutions together with the constant
concentration of type II receptor competitor cDNA, the
PCR products were separated by 3% agarose gel electropho-
resis (Fig. 4B). The ethidium-bromide-stained gel was then
densitometrically analyzed, and the intensities of both
bands were quantitated. It was apparent that the type II
receptor competitor band intensity decreased (from lane 1
to 10) while the type II receptor band intensity increased in
proportion to the amount of type II receptor cDNA included
in each tube. When the logarithm of the ratio of type II
receptor cDNA to its competitor PCR products was plotted
against the logarithm of the initial amount of mouse type II
receptor cDNA, a linear correlation (R2 0.95) was obtained
(Fig. 4C, open circles).
In the next step, sequential dilutions of the total RNA
FIG. 4. Competitive RT±PCR for TGF-b type II receptor mRNA extracted from mouse lung explant culture was reverse-
quantitation. (A). Competitive PCR products for TGF-b type II re- transcribed to form cDNA. Competitive PCR measure-
ceptor (IIR). Construction of TGF-b type II receptor and its competi-
ments of these reverse-transcribed cDNA products and ator is described under Materials and Methods. The black boxes
constant amount of type II receptor competitor (1.25 fg) isrepresent the primers I and II sites on both type II TGF-b receptor
shown (Fig. 4C, closed circles). The standard curves of re-(IIR) cDNA and its competitor. The hatched boxes in the competi-
verse-transcribed products had an identical slope to thetor represent the hybridization sites to heterogeneous cDNA. The
standard curve from recombinant TGF-b type II receptorTGF-b type II receptor and its competitor are 505 and 600 bp in
length, respectively. (B) Electrophoretic pattern of TGF-b type II
receptor (IIR) competitive PCR. PCR products separated in a 3%
agarose gel were stained by ethidium bromide. Lanes 1±10, PCR
products from 1:2 serial dilutions of mouse type II receptor cDNA
320, and 640 ng total RNA extracted from cultured embryonic(1, 0 fg; 2, 0.078125 fg; 3, 0.15625 fg; 4, 0.3125 fg; 5, 0.625 fg; 6,
lungs were reverse transcribed. Each reverse-transcribed mixture1.25 fg; 7, 2.5 fg; 8, 5.0 fg; 9, 10 fg; 10, 20 fg) and a constant 1.25-
was also coampli®ed with 1.25 fg TGF-b type II receptor competitorfg type II receptor competitor. An inverse relationship between
template. The resultant PCR products were electrophoresed,intensities of TGF-b type II receptor and its competitor is evident,
stained, and densitometrically stained. The log (cDNA/competitor)indicating competition between two templates. (C) Standard curve
was also plotted against the logarithm of the initial amount of totalfor TGF-b type II receptor competitive PCR. The log (TGF-b type
RNA being reverse transcribed (closed circles). The slope of theII receptor/its competitor) from densitometric data of ethidium-
highly linear regression line from reverse-transcribed RNA is al-bromide-stained agarose gel (B) was plotted against the logarithm of
most identical to the line derived from TGF-b type II receptorthe indicated amounts of added recombinant TGF-b type II receptor
cDNA. Both regression lines have R2 (coef®cient factor) valuescDNA template (open circles). A linear regression line with a high
greater than 0.95.coef®cient of correlation is shown. Next, 5, 10, 20, 40, 80, 160,
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cDNA (Fig. 4C). The identical slopes indicated that recom- tor ODN decreased TGF-b type II receptor mRNA levels in
lung explant cultures in a concentration-dependent fashionbinant type II receptor behaves identically in competitive
PCR to type II receptor cDNA made from reverse transcrip- (Fig. 5C).
tion. Therefore, the initial type II receptor mRNA in the
reverse transcriptase reaction can be quantitated using re-
Antisense Oligodeoxynucleotides Also Signi®cantlycombinant TGF-b type II receptor as a standard. Thus, the
Decreased TGF-b Type II Receptor Protein Level inlinear equation derived from a recombinant type II receptor
Lung CulturecDNA standard curve can be used to determine the un-
known amount of TGF-b type II receptor mRNA as its Individual lung explants treated with antisense TGF-b
type II receptor ODN were lysed with Triton X-100/NP-40cDNA equivalent. The detection limit for TGF-b type II
receptor was 0.078 fg cDNA or 5 ng total RNA in competi- lysis buffer to extract total protein. Five micrograms of total
protein extracted from media, 40 mM scrambled or antisensetive PCR (Fig. 4C).
ODN-treated lungs was electrophoresed and Western trans-
ferred to membrane, and this was followed by incubation
TGF-b Type II Receptor mRNA Measured by with anti-TGF-b type II receptor antibody. The type II recep-
Competitive RT±PCR Was Reduced in Cultured tor protein was then visualized using the chemilumines-
Lung Explants in the Presence of Antisense cence Western blotting kit from Boehringer Mannheim and
Oligodeoxynucleotides TGF-b type II receptor protein bands were densitometrically
scanned (Fig. 6A). In the presence of 40 mM antisense typeE11 lung explants were treated with TGF-b type II recep-
tor antisense oligodeoxynucleotides for 4 days. At the end II receptor ODN, the protein level was decreased to only
16% of control (Fig. 6B). In contrast, the scrambled 40 mMof the experimental period, individual lungs were extracted
for total RNA, which was subsequently reverse transcribed ODN showed a type II receptor protein level (80%) similar
to that of the media control. In the presence of the sameto generate cDNA. Fifty nanograms of reverse-transcribed
cDNA from each individual lung sample was then coampli- concentration of mismatched ODN, the protein level stayed
the same as the media control (data not shown). Thus, 40®ed with 1.25 fg type II receptor competitor cDNA in a TGF-
b type II competitive PCR assay. A typical electrophoretic mM TGF-b type II receptor antisense ODN effectively
blocked TGF-b type II receptor gene expression becausepattern is shown in Fig. 5A. The data show that TGF-b
type II receptor mRNA was signi®cantly diminished in the both its mRNA and protein levels were signi®cantly re-
duced. Therefore, we feel con®dent in attributing the stimu-presence of 40 mM antisense ODN. The standard curve
shown in Fig. 4 was utilized to quantitate the TGF-b type lation of lung branching morphogenesis in the presence of
TGF-b type II receptor antisense ODN to abrogation of typeII receptor mRNA level. The equation drawn from the linear
regression in Fig. 4C was used to extrapolate the TGF-b II receptor gene expression.
The antibody to TGF-b type II receptor is an Ig-G-puri®edtype II receptor mRNA amount from its cDNA equivalent
amount in each lung sample. To control for potential varia- polyclonal antibody which recognizes a major 70-kDa band
on a Western blot assay, corresponding to the size of TGF-tions due to the ef®ciency of RNA extraction and reverse
transcription, the housekeeping gene b-actin mRNA was b type II receptor. The band was diminished and its inten-
sity was greatly reduced by incubating antibody with excessalso quantitated in the same sample that TGF-b type II
receptor mRNA was measured. We designed the b-actin amount of antigen prior to blotting (data not shown), which
con®rmed that the 70-kDa band is indeed the type II recep-competitive PCR using a methodology similar to that de-
scribed above for TGF-b type II receptor. The electropho- tor band. Equal amounts of protein were used in each lane
for Western analysis.retic pattern for b-actin is shown in Fig. 5B. The b-actin
mRNA level was the same under all the conditions tested.
Therefore, TGF-b type II receptor mRNA level was normal-
TGF-b Type II Receptor mRNA and Protein Wereized to b-actin, and the results are shown in Fig. 5C.
Localized to Both Airway Epithelium andAntisense TGF-b type II receptor ODN treatment re-
Mesenchymal Tissuessulted in a dose-dependent decrease in TGF-b type II recep-
tor mRNA expression compared to the results of both TGF-b type II receptor mRNA was localized by in situ
hybridization in cultured lung explants (Fig. 7). In lung ex-scrambled ODN and media control. TGF-b type II receptor
antisense ODN (20 mM) reduced TGF-b type II receptor plants treated with scrambled (Fig. 7A), mismatched TGF-
b type II receptor ODN, or control media (not shown), TGF-mRNA by 20% compared to the media control, while the
20 mM scrambled ODN had no effect on type II receptor b type II receptor was observed in epithelial cells sur-
rounding developing airways as well as in mesenchymalmRNA amount (99% of media control). Antisense ODN 40
mM decreased the type II receptor mRNA level to only 5% cells. TGF-b type II receptor signal was also visualized in
the epithelial cells lining the developing airways in contactof the media control (P 0.05), while both 40mM scrambled
and mismatched ODNs failed to signi®cantly reduce the with mesenchymal cells. However, in lung culture treated
with antisense TGF-b type II receptor ODN (Fig. 7B), thetype II receptor mRNA level (94 and 93% of the media
control, respectively). Thus, antisense TGF-b type II recep- hybridization signal of type II receptor was decreased sig-
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FIG. 5. Inhibition of TGF-b type II receptor mRNA by antisense oligodeoxynucleotides (ODN). The 11-day embryonic lung explants
were treated with plain media as control (C), scrambled (SR) ODN (20 and 40 mM), mismatched (MM) ODN (40 mM), or antisense (AS)
ODN (20 and 40 mM) to TGF-b type II receptor mRNA as described under Materials and Methods. Treated lungs were used to generate
total RNA for reverse transcription. Only one single lung was used for each RNA extraction. In TGF-b type II receptor competitive PCR,
50 ng reverse-transcribed total RNA was added to 1.25 fg type II receptor competitor to perform competitive PCR. The electrophoretic
pattern for TGF-b type II receptor (IIR) competitive PCR is shown (A). By comparing to the standard curve (Fig. 4B), it is evident that type
II receptor mRNA is greatly reduced in 40 mM antisense (AS) ODN comparing with other conditions. In b-actin competitive PCR. Reverse-
transcribed RNA (20 ng) was coampli®ed with 0.5 pg b-actin competitor cDNA. Theb-actin competitive PCR standard curve is documented
previously. TGF-b type II receptor mRNA yield under each condition was thus normalized by the b-actin amount in the same sample.
Even by visual inspection of the b-actin electrophoretic pattern, it is evident that the b-actin amount is consistent in every condition (B).
C shows the TGF-b type II receptor mRNA level in each condition after b-actin normalization using medium control (C) as 100%. Type
II receptor mRNA levels are almost same in control (C), 20 mM scrambled (SR) ODN, 40 mM scrambled (SR) ODN, or 40 mM mismatched
(MM) ODN. In 40 mM antisense (AS) ODN, the type II receptor mRNA is greatly reduced comparing to controls (C, SR, and MM). Type
II receptor mRNA is also decreased, although to a lesser extent, in 20 mM antisense (AS) ODN treatment. Experiments were performed
with three lung samples under each condition and at least repeated for three times, although only single lung sample in each treatment
was shown in electrophoretic patterns in A and B. Each bar in C represents the mean { SD from triplicate samples.
ni®cantly, indicating a low level of TGF-b type II receptor competitive PCR construction for both cyclin A and cyclin
D1 was similar to that of TGF-b type II receptor. Electropho-mRNA in antisense ODN-treated lungs. The relative low
level of TGF-b type II receptor mRNA in antisense ODN- retic patterns and standard curves for both cyclin A and
cyclin D1 are shown in Fig. 8. Due to the linearity of cyclintreated lung explants as observed by in situ hybridization
correlated with the type II receptor mRNA measurement A and cyclin D1 competitive PCR standard curves, a visual
comparison of cyclin A or cyclin D1 mRNA amounts inby competitive RT±PCR (Fig. 5C). In the next step, TGF-b
type II receptor antigen was immunolocalized mainly in different samples was suf®cient. TGF-b1 reduced S-phase
cyclin A mRNA level relative to media control (Fig. 9),the airway epithelium (Fig. 7E) and to a lesser extent in
mesenchymal tissues. The intensity of TGF-b type II recep- indicating that cells in lung explants are arrested into G1
phase of the cell cycle in the presence of TGF-b1. TGF-btor immunostaining was much lower in antisense ODN-
treated lungs (Fig. 7F) in comparison with scrambled (Fig. type II receptor scrambled or mismatched (not shown) ODN
7E), mismatched or media control, which matched with the gave similar results to the media control. While antisense
Western blot results described above (Fig. 6). ODN complementary to TGF-b type II receptor effectively
inhibited its own mRNA expression, cyclin A mRNA ex-
pression remained at a level comparable to cyclin A mRNA
TGF-b Type II Receptor Antisense expression in the media or scrambled ODN controls.
Oligodeoxynucleotide Reversed the TGF-b1- Exogenous TGF-b1 exerted an inhibitory effect on cyclin
Mediated Downregulation of Cyclin A mRNA A mRNA expression not only when added alone but also
Level in the presence of scrambled ODN to type II receptor (Fig.
9). However, in the presence of antisense ODN to the TGF-Cyclin A and cyclin D1 levels in embryonic lung explants
were both measured by competitive PCR. Methodology of b type II receptor, TGF-b1 failed to decrease cyclin A
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cation of DNA (Tan et al., 1986; Prelich et al., 1987), was
also used as a marker of proliferation rate. In control (media)
lung explants, PCNA immunoreactivity was observed in
bronchial epithelium (Fig. 10A, a). In embryonic lungs
treated with 10 ng/ml TGF-b1, PCNA staining of cells was
reduced to minimal levels (b). However, in lungs treated
with 40 mM TGF-b type II receptor antisense ODN, PCNA-
staining cells were more prevalent than in media controls
(c). The relative increase in prevalence of PCNA-positive
cells in the presence of 40 mM antisense ODN to type II
receptor was not abolished with the addition of 10 ng/ml
exogenous TGF-b1 (d). The PCNA index (percentage of
PCNA-positive cells in bronchial epithelium) was obtained
by morphometry (Fig. 10B). Under each condition, the
PCNA index represents an average of at least 10 different
lung sections counted. In media controls, the PCNA index
was 41.1 { 10.6; 10 ng/ml TGF-b1 signi®cantly decreased
the PCNA index to only 15.3 { 3.2 (P  0.05), indicating a
decreased proportion of proliferating cells in murine bron-
chial epithelium. Antisense ODN to TGF-b type II receptor,
however, increased the PCNA index signi®cantly to 75.0 {
10.3 (P  0.05), while scrambled or mismatched ODNFIG. 6. Western analysis of TGF-b type II receptor protein expres-
yielded PCNA indexes similar to those of media controlssion. Cultured lungs were treated with plain medium (control, C),
(data not shown). The PCNA index remained high (70.2 {40 mM scrambled (SR), or 40 mM antisense (AS) ODNs as described
10.9) in the presence of both TGF-b type II receptor anti-in the legend to Fig. 5. Cultured lungs were used to extract total
protein. About 5 mg total protein was loaded in each lane and visual- sense ODN and TGF-b1 (Fig. 10B). However, exogenous
ized by using anti-TGF-b type II receptor antibody. From A, the blot TGF-b1 reduced the PCNA index in the presence of TGF-
shows clearly that type II receptor protein level is greatly reduced in b type II receptor scrambled or mismatched ODN (not
antisense (AS) treatment, while in scrambled (SR) ODN, the protein shown), similar to the effects of TGF-b1 alone. These results
level is about the same as that in medium control (C). Although indicate that abrogation of TGF-b type II receptor increases
only single lung sample was shown in the blot (A), B shows the
the bronchial epithelial cell proliferation rate, and that thisresults from three individual lungs under each condition. Data are
increment was not able to be reversed by addition of exoge-presented as means { SD by using medium control as 100%.
nous TGF-b1. Scattered PCNA-positive staining was also
observed in mesenchymal cells. Additionally, BrDU incor-
poration experiments yielded similar results to PCNA stain-
ing (not shown).mRNA level, while at the same time TGF-b type II receptor
mRNA was diminished. The ®nding of cyclin A mRNA
levels comparable to those of media controls in the presence
DISCUSSIONof both TGF-b type II receptor antisense ODN and TGF-
b1 indicates that abrogation of the TGF-b type II receptor
Our results demonstrate for the ®rst time that abrogationsignaling pathway prevents TGF-b-mediated G1-phase cell
of endogenous TGF-b type II receptor function upregulatescycle arrest. Thus, blockade of the TGF-b signaling pathway
early mouse embryonic lung branching morphogenesis inreverses the effects of endogenous TGF-b1 on embryonic
serumless culture, establishing the concept that endoge-lung cell proliferation. On the other hand, the mRNA
nous TGF-b signaling exerts negative regulation upon lungamounts of cyclin D1, a G1/S cyclin, stayed relatively stable
branching. The data presented herein also support the con-in comparison to cyclin A. b-actin mRNA levels were the
clusion that endogenous TGF-b1 and TGF-b2 possess dif-same among the samples assayed. The experiments were
fering potencies in attenuating branching morphogenesis.repeated at least three times and triplicate lung samples
The TGF-b gene family comprises a rapidly expandingwere used in each experiment. In each case, similar results
superfamily of polypeptides that differentially regulate cellto Fig. 9 were obtained.
proliferation, differentiation, chemotaxis, extracellular ma-
trix production, secretion of other growth factors, expres-
sion of cognate growth factor receptors and homeobox geneAbrogation of TGF-b Type II Receptor Increases
expression (Mercola and Stiles, 1988; Laiho et al., 1990;PCNA Staining in Embryonic Lung Epithelial Cells
Sporn and Robert, 1990; MassagueÂ et al., 1991; Moses et
al., 1991; Wang et al., 1991; Moustakas et al., 1993; VainioProliferating cell nuclear antigen (PCNA), a 36-kDa nu-
clear protein that is a cofactor for polymerase d during repli- et al., 1993; Lopez-Casilla et al., 1994; Wrana et al., 1994).
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FIG. 7. Localization of TGF-b type II receptor mRNA and protein. (A±D). In situ hybridization for TGF-b type II receptor mRNA. (E±
F). TGF-b type II receptor immunohistochemistry. In cultured embryonic lungs treated with TGF-b type II receptor scrambled ODN and
hybridized with antisense ribo-probe (A), TGF-b type II receptor mRNA was expressed in the epithelium of the developing airways (arrows)
as well as in the mesenchymal cells (arrowheads), while sense probe (C) only yielded negligible background on the adjacent section.
However, in the lungs treated with antisense ODN and hybridized with antisense ribo-probe (B), the intensity of TGF-b type II receptor
hybridization signal was signi®cantly decreased. Hematoxylin and eosin staining of a cultured lung section is shown in D. In TGF-b type
II receptor scrambled ODN-treated cultured lungs, TGF-b type II receptor protein was immunolocalized mainly in epithelial cells around
airways (arrows) while sparse immunostaining was also observed in mesenchymal cells (E, arrowheads). Much lower immunostaining
intensity was noted in TGF-b type II receptor antisense ODN-treated lung sections (F). aw, airways; m, mesenchyme. Magni®cation: 501.
TGF-b1, 2, and 3 mRNAs and peptides have been local- a key role in pulmonary morphogenesis (Heine et al., 1990;
Pelton et al., 1991). TGF-b3 null mutant mice have a neona-ized to distinct but overlapping temporospatial distribu-
tions in the branching regions of the embryonic and fetal tal lethal phenotype, features of which include delayed pul-
monary development and cleft palate, further supporting anlung, suggesting that endogenous TGF-b signaling may play
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FIG. 10. PCNA immunostaining in lung explant cultures. (A) PCNA staining in lung sections as revealed by immunohistochemistry
(bar, 20 mm). PCNA staining was seen in control lungs (a), while only minimal PCNA staining was observed in TGF-b1 (10 ng/ml)-treated
lungs (b). An increase of PCNA staining in TGF-b type II receptor antisense ODN (40mM)-treated lungs was shown (c) and this upregulation
could not be reversed with addition of 10 ng/ml exogenous TGF-b1 (d). (B) PCNA staining in embryonic bronchial epithelium as expressed
by PCNA index. The PCNA index is the number of PCNA-positive nuclei divided by the total number of nuclei (shown in A). The PCNA
index in each group is signi®cantly different from the other (P  0.05) except AS-IIR and AS-IIR/TGF-b1 (P  0.27).
essential function for endogenous TGF-b signaling in criti- ure of the palatal medial edge epithelium to fuse in the
midline, at a time and location where TGF-b3 is highlycal embryonic epithelial ±mesenchymal interactions (Kaar-
tinen et al., 1995). In contrast, TGF-b1 null mutant mice expressed in the wild-type embryo (Ferguson, 1988). TGF-
b3 gene expression is also strongly induced in response toexhibit a normal neonatal lung phenotype and this has been
attributed to maternal transplacental rescue by TGF-b1 corticosteroid treatment of fetal lung ®broblasts (Wang et
al., 1995), suggesting that the well-recognized salutary ef-transferred from the maternal circulation: TGF-b3 null mu-
tant mouse embryos appear to be refractory to maternal fects of glucocorticoids on late fetal lung may in part be
mediated by stimulation of temporospatially restrictedtransplacental rescue. TGF-b3 null mutation results in fail-
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FIG. 8. Competitive PCR for cyclin A (A) and cyclin D1 (B) mRNA quantitation. (A) 0, 0.625, 1.25, 2.5, 5, 10, 20, 40, 80, or 160 fg cyclin
A cDNA was used to coamplify with a constant amount of 10 fg cyclin A competitor cDNA. Electrophoretic pattern (ethidium bromide
staining) after PCR ampli®cation is shown. The intensity of each band was densitometrically scanned and the logarithm of (cyclin A/
competitor) was plotted against the initial amount of cyclin A cDNA used in competitive PCR reaction. Thus, a linear line (R2  0.95)
was obtained. Cyclin A-competitive PCR using different amount of reverse-transcribed RNA (from 1.25 to 40 ng total RNA) and same 10
fg cyclin A cDNA also yielded a linear line with almost same slope similar to the line from cyclin A cDNA. (B) 0, 0.125, 0.25, 0.5, 1, 2,
4, 8, 16, or 32 fg cyclin D1 cDNA was used in PCR to coamplify with a known amount of 2 fg cyclin D1 competitor. Following
electrophoresis, ethidium-bromide-stained gel was scanned and band intensities were thus determined densitometrically. Similarly, the
logarithm of (cyclin D1/competitor) was used to plot against the cyclin D1 amounts in competitive PCR. Therefore, a linear line (R2 
0.95) was obtained. The slope of this linear line is identical to the linear line derived from a serial dilution of reverse-transcribed RNA
(from 1.25 to 40 ng total RNA) in cyclin D1 competitive PCR.
TGF-b3 gene expression. Taken together, these results indi- pression of TGF-b type II receptor mutants lacking the
cytoplasmic kinase domain results in nearly completecate that highly localized expression and signaling at the
mesenchymal±epithelial interface by speci®c TGF-b pep- loss of TGF-b-dependent growth inhibition, but not TGF-
b-dependent stimulation of ®bronectin synthesis, plas-tides with widely different potencies and speci®cities is im-
portant in pulmonary morphogenesis. TGF-b type II recep- minogen-activator inhibitor (PAI-1) expression, and on-
cogene mRNAs (Chen et al., 1993). Thus, under sometor mRNA and protein are coexpressed with the TGF-b type
I receptor in this critical epithelial ±mesenchymal microen- circumstances receptor-speci®c signaling can occur, with
growth inhibition transduced by the type II receptor andvironment (Iseki et al., 1995; Zhao and Young, 1995).
TGF-b ligands are presented to the TGF-b type II recep- matrix gene regulation by the type I receptor. The anti-
sense ODN strategy used herein speci®cally and ef®-tor by the TGF-b type III receptor (Lopez-Castillas et al.,
1993, 1994). The TGF-b type I receptor requires the TGF- ciently abrogated TGF-b type II receptor gene expression
both at the transcriptional and translational levels. Theb type II receptor in order to bind ligand and TGF-b type
I receptor and type II receptor interact physically in het- immunoperturbation strategy used herein also effec-
tively blocks TGF-b ligand binding to TGF-b type I recep-erooligomeric complexes (Wrana et al., 1992; Inagaki et
al., 1993). Both TGF-b type I and type II receptors mediate tors without completely blocking ligand binding to type
II or type III receptors, indicating a selective disruptionbiological responses through mechanisms involving their
intrinsic serine/threonine kinase activities. Overex- of TGF-b receptor heterooligomers, and therefore block-
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ade of TGF-b type I receptor association with and activa-
tion by TGF-b type II receptor (Hall et al., 1996).
We also observed increased cyclin A mRNA expression
and PCNA staining of nuclei following abrogation of TGF-
b type II receptor function by immunoperturbation or anti-
sense oligodeoxynucleotide blockade. These effects were re-
fractory to exogenous TGF-b1. Therefore, abrogation of
TGF-b type II receptor signaling appears to release negative
regulation of the cell cycle by endogenous TGF-b peptide
signaling. Moreover, endogenous TGF-b signaling through
the TGF-b type II receptor appears to exert opposite effects
on DNA synthesis and branching morphogenesis to those
of EGF signaling through EGF receptor which stimulates
embryonic lung branching morphogenesis and organ DNA
content (Warburton et al., 1992; Seth et al., 1993; Miettinen
et al., 1995).
In summary, we conclude that endogenous TGF-bpeptide
signaling through the TGF-b type II receptor exerts negative
control on the process of early embryonic murine lung mor-
phogenesis in culture. This negative regulation is released
by abrogation of TGF-b type II receptor function using ei-
ther immunoperturbation or antisense ODN as experimen-
tal approaches. We speculate that endogenous TGF-b signal-
ing through the TGF-b type II receptor may serve to nega-
tively modulate and therefore balance the positive
functions of signaling by other cognate peptide growth fac-
tor receptor pathways including EGF, PDGF, ands bFGF
which are known to exert inductive or permissive in¯uence
on lung morphogenesis (Warburton et al., 1992; Miettinen
et al., 1995; Souza et al., 1995; BostroÈm et al., 1996).
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